Document Detail


Statins and diabetes: the good, the bad, and the unknown.
MedLine Citation:
PMID:  23299640     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The ability for statins to reduce major cardiovascular events and mortality has lead to this drug class being the most commonly prescribed in the world. In particular, the benefit of these drugs in type 2 diabetes (T2D) is well established. In February 2012, the Food and Drug Administration released changes to statin safety label to include that statins have been associated with increases in hemoglobin A1C and fasting serum glucose levels. This has stirred much debate in the medical community. Estimate for new onset diabetes from statin treatment is approximately one in 255 patients over four years. The number needed to treat for statin benefit is estimated at one in 40 depending on the population. The mechanism of this link remains unknown. Statins may accelerate progression to diabetes via molecular mechanisms that impact insulin resistance and cellular metabolism of carbohydrates. It remains clear that the benefit of statin therapy outweighs the risk of developing diabetes.
Authors:
Kelly Axsom; Jeffrey S Berger; Arthur Z Schwartzbard
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  15     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  299     Citation Subset:  IM    
Affiliation:
Department of Medicine, Division of Cardiology, NYU Langone Medical Center, 530 First Avenue, Skirball 9U, New York, NY, 10016, USA, Kelly.Axsom@nyumc.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The evolution or revolution of statin therapy in primary prevention: where do we go from here?
Next Document:  Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of stat...